3R,4S-dihydroxy-5S-(1,2,3-trihydroxypropyl)dihydrofuran-2(3H)-one | 1561720-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 3R,4S-dihydroxy-5S-(1,2,3-trihydroxypropyl)dihydrofuran-2(3H)-one
• 英文别名: (3R,4S,5S)-3,4-dihydroxy-5-(1,2,3-trihydroxypropyl)oxolan-2-one
• CAS: 1561720-89-5
• 化学式: C₇H₁₂O₇
• 分子量: 208.168
• InChiKey: VIVCRCODGMFTFY-AOHHLDIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Prion protein ligands as therapeutic agents for neurodegenerative disorders
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US10391068B2

  公开（公告）日：2019-08-27

  The invention provides compositions and methods for treatment of neurodegenerative diseases or disorders, particularly neurodegenerative diseases and disorders associated with protein aggregation. The present invention is based on the discovery of binding regions on the surface of PrPc, referred to as PrPc Binding Domains (PBD). In particular, the inventors have identified six different binding regions on PrPc, referred to herein as PrP-binding domain-1 (PBD-1), PrP-binding domain-2 (PBD-2), PrP-binding domain-3 (PBD-3), PrP-binding domain-4 (PBD-4), PrP-binding domain-5 (PBD-5), and PrP-binding domain-6 (PBD-6), herein. The PBD-1 to PBD-6 are each defined by a cluster of amino acids located in the globular domain of the protein, e.g., in the C-terminal half of the protein (i.e., in residues 120-230). One embodiment uses residues 127-226.

  本发明提供了治疗神经退行性疾病或紊乱的组合物和方法，特别是与蛋白质聚集相关的神经退行性疾病和紊乱。本发明基于 PrPc 表面结合区的发现，这些结合区被称为 PrPc 结合区（PBD）。特别是，本发明者在 PrPc 上发现了六个不同的结合区域，在此称为 PrP 结合域-1 (PBD-1)、PrP 结合域-2 (PBD-2)、PrP 结合域-3 (PBD-3)、PrP 结合域-4 (PBD-4)、PrP 结合域-5 (PBD-5) 和 PrP 结合域-6 (PBD-6)。PBD-1 至 PBD-6 分别由位于蛋白质球状结构域中的一组氨基酸定义，例如位于蛋白质的 C 端半部（即残基 120-230）。一个实施方案使用残基 127-226。
• Seven-membered ring nucleosides
  申请人：Storer Richard

  公开号：US20070185063A1

  公开（公告）日：2007-08-09

  The present invention provides nucleoside analogue compounds that treat a host infected with a Flaviviridae virus infection, or other viruses that exhibit RNA-dependent RNA viral replication, compositions comprising these compounds and methods of using the compounds for the treatment and/or prophylaxis of viral infection, especially hepatitis C, in an infected host.
• PRION PROTEIN LIGANDS AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US20150196508A1

  公开（公告）日：2015-07-16

  The invention provides compositions and methods for treatment of neurodegenerative diseases or disorders, particularly neurodegenerative diseases and disorders associated with protein aggregation. The present invention is based on the discovery of binding regions on the surface of PrPc, referred to as PrPc Binding Domains (PBD). In particular, the inventors have identified six different binding regions on PrPc, referred to herein as PrP-binding domain-1 (PBD-1), PrP-binding domain-2 (PBD-2), PrP-binding domain-3 (PBD-3), PrP-binding domain-4 (PBD-4), PrP-binding domain-5 (PBD-5), and PrP-binding domain-6 (PBD-6), herein. The PBD-1 to PBD-6 are each defined by a cluster of amino acids located in the globular domain of the protein, e.g., in the C-terminal half of the protein (i.e., in residues 120-230). One embodiment uses residues 127-226.
• [EN] PRION PROTEIN LIGANDS AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS<br/>[FR] LIGANDS DE PROTÉINE PRION EN TANT QU'AGENTS THÉRAPEUTIQUES POUR DES TROUBLES NEURODÉGÉNÉRATIFS
  申请人：UNIV BOSTON

  公开号：WO2014025785A2

  公开（公告）日：2014-02-13

  The invention provides compositions and methods for treatment of neurodegenerative diseases or disorders, particularily neurodegenerative diseases and disoders associated with protein aggregration.